Immune response and prophylactic efficacy of smegmosomes in a hamster model of leptospirosis

Vaccine

Volumn 27, Issue 44, 2009, Pages 6129-6136

  Faisal, Syed M ^a   Yan, WeiWei ^a   McDonough, Sean P ^a   Mohammed, Hussni O ^a   Divers, Thomas J ^a   Chang, Yung Fu ^a  

^a Department of Molecular Biology and Genetics   (United States)

Author keywords

Adjuvant; Leptospira interrogans; Liposome; M. smegmatis

Indexed keywords

ALUMINUM HYDROXIDE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; LEPTOSPIROSIS VACCINE; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEMALE; HAMSTER; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; LEPTOSPIRA INTERROGANS; LEPTOSPIROSIS; LETHAL DOSE; LYMPHOCYTE PROLIFERATION; MYCOBACTERIUM SMEGMATIS; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SPLEEN CELL; SURVIVAL; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; CELL PROLIFERATION; CRICETINAE; DISEASE MODELS, ANIMAL; FEMALE; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-4; LEPTOSPIRA INTERROGANS SEROVAR POMONA; LEPTOSPIROSIS; LIPOSOMES; MYCOBACTERIUM SMEGMATIS; RECOMBINANT PROTEINS;

EID: 70349785161     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.08.029     Document Type: Article

References (52)

1. Haake D.A., Dundoo M., Cader R., Kubak B.M., Hartskeerl R.A., Sejvar J.J., et al. Leptospirosis, water sports, and chemoprophylaxis. Clin Infect Dis 34 9 (2002) e40-e43
2. Meites E., Jay M.T., Deresinski S., Shieh W.J., Zaki S.R., Tompkins L., et al. Reemerging leptospirosis California. Emerg Infect Dis 10 3 (2004) 406-412
3. Morgan J., Bornstein S.L., Karpati A.M., Bruce M., Bolin C.A., Austin C.C., et al. Outbreak of leptospirosis among triathlon participants and community residents in Springfield, Illinois, 1998. Clin Infect Dis 34 12 (2002) 1593-1599
4. Ricaldi J.N., and Vinetz J.M. Leptospirosis in the tropics and in travelers. Curr Infect Dis Rep 8 1 (2006) 51-58
5. Sejvar J., Bancroft E., Winthrop K., Bettinger J., Bajani M., Bragg S., et al. Leptospirosis in "Eco-Challenge" athletes, Malaysian Borneo, 2000. Emerg Infect Dis 9 6 (2003) 702-707
6. McBride A.J., Athanazio D.A., Reis M.G., and Ko A.I. Leptospirosis. Curr Opin Infect Dis 18 5 (2005) 376-386
7. Andre-Fontaine G., Branger C., Gray A.W., and Klaasen H.L. Comparison of the efficacy of three commercial bacterins in preventing canine leptospirosis. Vet Rec 153 6 (2003) 165-169
8. Bharti A.R., Nally J.E., Ricaldi J.N., Matthias M.A., Diaz M.M., Lovett M.A., et al. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis 3 12 (2003) 757-771
9. Bolin C.A., Thiermann A.B., Handsaker A.L., and Foley J.W. Effect of vaccination with a pentavalent leptospiral vaccine on Leptospira interrogans serovar Hardjo type hardjo-bovis infection of pregnant cattle. Am J Vet Res 50 1 (1989) 161-165
10. Faine SB, Adher B, Bolin C, Perolat P, editors. Leptospira and Leptospirosis. Medbourne, Australia: Med Sci, 1999.
11. Levett P.N. Leptospirosis. Clin Microbiol Rev 14 2 (2001) 296-326
12. Sonrier C., Branger C., Michel V., Ruvoen-Clouet N., Ganiere J.P., and Andre-Fontaine G. Evidence of cross-protection within Leptospira interrogans in an experimental model. Vaccine 19 1 (2000) 86-94
13. Baldwin C.L., Sathiyaseelan T., Naiman B., White A.M., Brown R., Blumerman S., et al. Activation of bovine peripheral blood gammadelta T cells for cell division and IFN-gamma production. Vet Immunol Immunopathol 87 3-4 (2002) 251-259
14. Klimpel G.R., Matthias M.A., and Vinetz J.M. Leptospira interrogans activation of human peripheral blood mononuclear cells: preferential expansion of TCR gamma delta+ T cells vs TCR alpha beta+ T cells. J Immunol 171 3 (2003) 1447-1455
15. Naiman B.M., Alt D., Bolin C.A., Zuerner R., and Baldwin C.L. Protective killed Leptospira borgpetersenii vaccine induces potent Th1 immunity comprising responses by CD4 and gammadelta T lymphocytes. Infect Immun 69 12 (2001) 7550-7558
16. Naiman B.M., Blumerman S., Alt D., Bolin C.A., Brown R., Zuerner R., et al. Evaluation of type 1 immune response in naive and vaccinated animals following challenge with Leptospira borgpetersenii serovar Hardjo: involvement of WC1(+) gammadelta and CD4 T cells. Infect Immun 70 11 (2002) 6147-6157
17. Burnette W.N. Recombinant subunit vaccines. Curr Opin Biotechnol 2 6 (1991) 882-892
18. Chang Y.F., Chen C.S., Palaniappan R.U., He H., McDonough S.P., Barr S.C., et al. Immunogenicity of the recombinant leptospiral putative outer membrane proteins as vaccine candidates. Vaccine 25 48 (2007) 8190-8197
19. Faisal S.M., Yan W., McDonough S.P., and Chang Y.F. Variable region of Leptospira immunoglobulin like protein A (LigAvar) incorporated in Liposomes and PLGA-Microspheres produces a robust immune response correlating to protective immunity against challenge in hamsters. Vaccine 27 (2009) 378-387
20. Haake D.A., Mazel M.K., McCoy A.M., Milward F., Chao G., Matsunaga J., et al. Leptospiral outer membrane proteins OmpL1 and LipL41 exhibit synergistic immunoprotection. Infect Immun 67 12 (1999) 6572-6582
21. Koizumi N., and Watanabe H. Leptospiral immunoglobulin-like proteins elicit protective immunity. Vaccine 22 11-12 (2004) 1545-1552
22. Palaniappan R.U., McDonough S.P., Divers T.J., Chen C.S., Pan M.J., Matsumoto M., et al. Immunoprotection of recombinant leptospiral immunoglobulin-like protein A against Leptospira interrogans serovar Pomona infection. Infect Immun 74 3 (2006) 1745-1750
23. Seixas F.K., da Silva E.F., Hartwig D.D., Cerqueira G.M., Amaral M., Fagundes M.Q., et al. Recombinant Mycobacterium bovis BCG expressing the LipL32 antigen of Leptospira interrogans protects hamsters from challenge. Vaccine 26 1 (2007) 88-95
24. Silva E.F., Medeiros M.A., McBride A.J.A., Matsunaga J., Esteves G.S., Ramos J.G.R., et al. The terminal portion of leptospiral immunoglobulin-like protien A confers protective immunity against lethal infection in the hamster model of leptospirosis. Vaccine 25 (2007) 6277-6286
25. Yan W., Faisal S.M., McDonough S.P., Divers T.J., Barr S.C., Chang C.F., et al. Immunogenicity and protective efficacy of recombinant Leptospira immunoglobulin-like protein B (rLigB) in a hamster challenge model. Microb Infect 11 2 (2009) 230-237
26. Gupta R.K. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 32 3 (1998) 155-172
27. Gupta R.K., Relyveld E.H., Lindblad E.B., Bizzini B., Ben-Efraim S., and Gupta C.K. Adjuvants-a balance between toxicity and adjuvanticity. Vaccine 11 3 (1993) 293-306
28. Relyveld E.H., Bizzini B., and Gupta R.K. Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids. Vaccine 16 9-10 (1998) 1016-1023
29. Sprott G.D., Dicaire C.J., Gurnani K., Sad S., and Krishnan L. Activation of dendritic cells by liposomes prepared from phosphatidylinositol mannosides from Mycobacterium bovis bacillus Calmette-Guerin and adjuvant activity in vivo. Infect Immun 72 9 (2004) 5235-5246
30. Rosenkrands I., Agger E.M., Olsen A.W., Korsholm K.S., Andersen C.S., Jensen K.T., et al. Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system. Infect Immun 73 9 (2005) 5817-5826
31. Faisal S.M., Yan W., Chen C.S., Palaniappan R.U., McDonough S.P., and Chang Y.F. Evaluation of protective immunity of Leptospira immunoglobulin like protein A (LigA) DNA vaccine against challenge in hamsters. Vaccine 26 2 (2008) 277-287
32. Bligh E.G., and Dyer W.J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37 8 (1959) 911-917
33. Kirby C.J., and Gregoriadis G. Preparation of liposomes containing factor VIII for oral treatment of haemophilia. J Microencapsul 1 1 (1984) 33-45
34. Alving C.R. Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens. Biochim Biophys Acta 1113 3-4 (1992) 307-322
35. O'Hagan D.T., Jeffery H., Roberts M.J., McGee J.P., and Davis S.S. Controlled release microparticles for vaccine development. Vaccine 9 10 (1991) 768-771
36. O'Hagan D.T., Rahman D., McGee J.P., Jeffery H., Davies M.C., Williams P., et al. Biodegradable microparticles as controlled release antigen delivery systems. Immunology 73 2 (1991) 239-242
37. Gregoriadis G. Immunological adjuvants: a role for liposomes. Immunol Today 11 3 (1990) 89-97
38. Kirby D.J., Rosenkrands I., Agger E.M., Andersen P., Coombes A.G., and Perrie Y. Liposomes act as stronger sub-unit vaccine adjuvants when compared to microspheres. J Drug Target 16 7 (2008) 543-554
39. Perrie Y. Gregory Gregoriadis: Introducing liposomes to drug delivery. J Drug Target 16 7 (2008) 518-519
40. Perrie Y., Mohammed A.R., Kirby D.J., McNeil S.E., and Bramwell V.W. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int J Pharm 364 2 (2008) 272-280
41. Singh M., and O'Hagan D.T. Recent advances in vaccine adjuvants. Pharm Res 19 6 (2002) 715-728
42. Bovier P.A. Epaxal: a virosomal vaccine to prevent hepatitis A infection. Expert Rev Vaccines 7 8 (2008) 1141-1150
43. Davidsen J., Rosenkrands I., Christensen D., Vangala A., Kirby D., Perrie Y., et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta 1718 1-2 (2005) 22-31
44. Faisal S.M., Khan M.A., Nasti T.H., Ahmad N., and Mohammad O. Antigen entrapped in the escheriosomes leads to the generation of CD4(+) helper and CD8(+) cytotoxic T cell response. Vaccine 21 19-20 (2003) 2383-2393
45. Krishnan L., Dicaire C.J., Patel G.B., and Sprott G.D. Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: comparison to conventional liposomes and alum. Infect Immun 68 1 (2000) 54-63
46. Fruend J. The mode of action of immunologic adjuvants. Bibl Tuberc 10 (1956) 130-148
47. Holten-Andersen L., Doherty T.M., Korsholm K.S., and Andersen P. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect Immun 72 3 (2004) 1608-1617
48. Koike Y., Yoo Y.C., Mitobe M., Oka T., Okuma K., Tono-oka S., et al. Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine. Vaccine 16 20 (1998) 1982-1989
49. McBride B.W., Mogg A., Telfer J.L., Lever M.S., Miller J., Turnbull P.C., et al. Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine 16 8 (1998) 810-817
50. Nossal G. Antigens. Lymphoid cells and the immune response (1971), Academic Press, New Yrok
51. Zinkernagel R.M., Ehl S., Aichele P., Oehen S., Kundig T., and Hengartner H. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 156 (1997) 199-209
52. Sprott G.D., Dicaire C.J., Gurnani K., Deschatelets L.A., and Krishnan L. Liposome adjuvants prepared from the total polar lipids of Haloferax volcanii. Planococcus spp. and Bacillus firmus differ in ability to elicit and sustain immune responses. Vaccine 22 17-18 (2004) 2154-2162